CGBio History
History
2020’s
- 2023
- Selected as a company that achieved revenues of one hundred billion won
- Establishment of CGMedTech Corporation in the USA
- S-Campus Brazil BGMP Certification
- Establishment of NULOOK Medical Aesthetic Clinic
- Acquisition of M.Base, a specialist in lifting threads
- 2022
- Selected as Hi-Seoul Business
- Obtained authorization for a cell processing facility
- Concluded NOVOSIS license outsourcing agreement in North America with Orthofix (USA)
- Selected as an Outstanding Enterprise for Compensation for Employee’s Invention
- Established CGBIO NEOREGEN Indonesia
- 2021
- Selected as a Great Place to Work by the Korea Chamber of Commerce and Industry
- Commendation from the Minister of Health and Welfare as an Innovative Medical Appliance Enterprise
- Commendation for Merit in SME Growth and Development
- Obtained certification for quality management system from the American Association of Tissue Banks (AATB)
- CE certification for HA Filler (GISELLELIGNE, VOM)
- 2020
- Obtained CE certification in Europe for Facetem S, EXCELOS Inject, and CG GEL
- Selected as a Global Hidden Champion
- Selected as a Great Place to Work in Gyeonggi-do
- Selected as a Great Place to Work (Medical Appliance SC)
- Selected as an Innovative Medical Appliance Enterprise
- Awarded the USD 7 Million Export Tower Award
- Selected as a Promising SME in Gyeonggi-do
2010’s
- 2019
- Selected as a Family-friendly Workplace
- Awarded the USD 3 Million Export Tower Award
- Cerebrovascular stent ‘Alpha Stent’ first authorized in Korea
- IR52 Jang Young-sil Award – NOVOSIS
- Presidential citation for Gender Equality in Employment
- Cosmetic surgery filler ‘GISELLELIGNE’ authorized by CFDA in China
- 2018
- Certified as an Outstanding R&D Center by the Ministry of Science and Technology
- 2017
- Selected as the Next-gen World Class Product by the Ministry of Trade, Industry and Energy (NOVOSIS)
- Certified as an Outstanding Enterprise for Compensation for Employee’s Invention
- Two certifications for new health technology by the Ministry of Health and Welfare (NET): EGF Endoscopy Gel, NOVOSIS
- Biofusion medical appliance (rhBMP-2) ‘NOVOSIS’ first authorized in Korea
- 2016
- New Technology Certification for treatment for Hemorrhagic Gastrointestinal Disease Treatment for Endoscopy using epithelial cell growth factor
- Received IR52 Jang Young-Sil Award for Technological Innovation
- First approval in Korea of NOVOSIS, a medical device with fusion of bone graft-promoting protein ‘rhBMP-2’ and bone graft material
- Selected as an Excellent Technology Research Center from Ministry of Trade, Industry and Energy.
- Acquirement of certification for New Health Technology (NET)
- 2015
- Achieved ‘Million Dollar Export Tower’ on Trade Day
- Jang Young-Sil Award / Minister of Industry Award / Certified for New Health Technology
- 2013
- CE Certification
- Acquired FDA approval for CuraVAC (medical device)
- 2011
- ISO 13485 Granted
- 2010
- Medical equipment manufacturing license register
- Approval of Good Manufacturing Practice Regulations (GMP)
2000’s
- 2009
- Inobiz Accreditation/Certification
- 2008
- Human Tissue FDA Registration / Registration as a venture company
- 2007
- Tissue bank authorization/ establishment of Corporate Research Center
- 2006
- Founding of CGBio